Local synthesis of vasoactive peptides, e.g. angiotensin, may be one of several mechanisms by which vascular endothelium participate in the control of vascular function. Multiple lines of evidence support the existence of a vascular wall renin-angiotensin system (RAS) which is independent of the circulating system. Immunohistochemical and biochemical studies have demonstrated that components of the renin-angiotensin system exist in blood vessel walls especially in the intima. Using cultured bovine aortic endothelial cells (BAEC), we documented intracellular renin-angiotensin expression (Circ. Res. 58:312, 1985). More recently, using monoclonal antibodies to human renin, we detected immunoreactive renin in cultured human iliac artery endothelial cell, by both direct radioimmunoassay and immunocytochemistry. Using HPLC and radioimmunoassay, we have been able to demonstrate angiotensins both intracellularly in BAEC and in the culture media where the peptides accumulate in a time-dependent manner. We have been unable to detect renin or angiotensinogen in the media. Taken together, our data suggest that cultured aortic endothelial cells contain the renin-angiotensin system and that the renin-angiotensinogen reaction occurs principally inside the cells. Angiotensin is then secreted extracellularly where it may exert its action. We propose to carry out an in-depth study on the biology of the endothelial renin-angiotensin pathway. Issues to be studied are: (1) the biochemical characterization and the subcellular localization of the various components of this intracellular renin-angiotensin system, (2) the regulation of this local system, especially the regulation of angiotensin secretion, and (3) the identification of the function(s) of endothelial renin-angiotensin system. We postulate that endothelial production of angiotensins is locally regulated and these peptides may exert autocrine or paracrine influences on the blood vessel wall, thereby affecting local vascular tone. By elucidating the cellular mechanisms of angiotensin synthesis and secretion as well as the factors which regulate these processes, we should improve our understanding of the biology of this fundamental cardiovascular regulatory system.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL035252-05
Application #
3348966
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1990-09-01
Project End
1991-05-31
Budget Start
1990-09-01
Budget End
1991-05-31
Support Year
5
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Tomita, Naruya; Kim, John Y S; Gibbons, Gary H et al. (2004) Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int J Mol Med 13:629-36
Akishita, M; Shirakami, G; Iwai, M et al. (2001) Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice. J Hypertens 19:1083-8
Daviet, L; Lehtonen, J Y; Hayashida, W et al. (2001) Intracellular third loops in AT1 and AT2 receptors determine subtype specificity. Life Sci 69:509-16
Tomita, N; Morishita, R; Tomita, S et al. (2000) Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 7:1326-32
Horiuchi, M; Hayashida, W; Akishita, M et al. (2000) Interferon-gamma induces AT(2) receptor expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1. Circ Res 86:233-40
Akishita, M; Iwai, M; Wu, L et al. (2000) Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102:1684-9
Yamada, H; Akishita, M; Ito, M et al. (1999) AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 33:1414-9
Lehtonen, J Y; Daviet, L; Nahmias, C et al. (1999) Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. Mol Endocrinol 13:1051-60
Lehtonen, J Y; Horiuchi, M; Daviet, L et al. (1999) Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 274:16901-6
Horiuchi, M; Hayashida, W; Akishita, M et al. (1999) Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 84:876-82

Showing the most recent 10 out of 91 publications